Fig. 5.
Fig. 5. Survival after leukemia induction (B6 Ly-5a→ B6D2F1). B6 Ly-5a donors were injected with or without G-CSF for 6 days. (A) Total body irradiated B6D2F1 mice received 1 × 107 splenocytes plus 5,000 p815 tumor cells from control B6 donors (n = 15), G-CSF–mobilized donors (n = 20), or control B6D2F1 donors (n = 13). *P < .001 vrecipients of splenocytes from control B6 donors and control B6D2F1 donors. (B) Total body irradiated B6D2F1 recipients were injected with 5 × 106 TCD-splenocytes plus 5,000 p815 tumor cells from control or G-CSF B6 donors (n = 8/group). Survival was monitored daily up to day 70 posttransplantation.

Survival after leukemia induction (B6 Ly-5a→ B6D2F1). B6 Ly-5a donors were injected with or without G-CSF for 6 days. (A) Total body irradiated B6D2F1 mice received 1 × 107 splenocytes plus 5,000 p815 tumor cells from control B6 donors (n = 15), G-CSF–mobilized donors (n = 20), or control B6D2F1 donors (n = 13). *P < .001 vrecipients of splenocytes from control B6 donors and control B6D2F1 donors. (B) Total body irradiated B6D2F1 recipients were injected with 5 × 106 TCD-splenocytes plus 5,000 p815 tumor cells from control or G-CSF B6 donors (n = 8/group). Survival was monitored daily up to day 70 posttransplantation.

Close Modal

or Create an Account

Close Modal
Close Modal